Related Experiment Video
Updated: Jul 7, 2025
10:03
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
25.8K
Drug Therapies for Diabetes
Roni Weinberg Sibony1, Omri Segev2, Saar Dor1
1Faculty of Medicine, Ben-Gurion University, Beer Sheva 8443944, Israel.
International Journal of Molecular Sciences
|December 23, 2023
Summary
Effective type 2 diabetes (T2D) management requires lifestyle changes and medications like metformin, GLP-1 RAs, and SGLT-2i. Novel dual agonists offer enhanced benefits for glycemic control and weight reduction.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Type 2 diabetes (T2D) management requires a comprehensive strategy combining behavioral and pharmacological interventions.
- Effective control of glucose levels, weight, cardiovascular risk factors, and comorbidities is crucial for preventing complications and maintaining quality of life.
Purpose of the Study:
- To review the current landscape of pharmacotherapy for T2D.
- To evaluate the efficacy, target organ impact, and side effects of available diabetes medications.
- To provide insights for customizing T2D treatment strategies.
Main Methods:
- Comprehensive literature review of T2D pharmacotherapy.
- Analysis of current treatment guidelines and drug efficacy data.
- Evaluation of novel therapeutic agents and combination therapies.
Main Results:
- Metformin remains a first-line oral agent due to efficacy, versatility, and cost-effectiveness.
- GLP-1 receptor agonists (GLP-1 RA) and SGLT-2 inhibitors (SGLT-2i) offer significant benefits for HbA1c, weight, cardiovascular, renal, and heart failure outcomes.
- Dual GLP-1/GIP agonists show promise for substantial reductions in HbA1c and body weight.
Conclusions:
- Combined therapies and early glycemic control are key to effective T2D management.
- Metformin, GLP-1 RA, and SGLT-2i are vital non-insulin agents, with insulin therapy remaining pivotal.
- Personalized treatment strategies incorporating novel agents are essential for optimizing T2D care.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
288
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
288
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
207
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
207
01:22Diabetes Mellitus: Overview and Type I Subtype
2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K
01:22Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
01:24Glucagon-like Receptor Agonists
327
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
327
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
179
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
179